Severe fever with thrombocytopenia syndrome in Hefei: Clinical features, risk factors, and ribavirin therapeutic efficacy.

This study described the clinical features, risk factors, factors affecting the outcome of this disease, and ribavirin therapeutic efficacy for severe fever with thrombocytopenia syndrome (SFTS) patients in Hefei. Between April 2020 and July 2020, 62 cases admitted to the First Affiliated Hospital of Anhui Medical University were included in this study. Serum samples were collected from all patients, after which diagnosis was made via reverse transcription-polymerase chain reaction and via the use of a colloidal gold immunochromatography assay approach. In multivariate analysis, the following factors were determined as risk factors for SFTS: Being a farmer (odds ratio [OR], 3.033), working in areas with weeds and shrubs (OR, 2.807), and being bitten by a tick (OR, 6.64). The rates of confusion, neck stiffness, viral encephalopathy, and the presence of liver damage were higher in the patients who died than that in the surviving ones. Additionally, the median of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatine phosphokinase, activated partial thromboplastin time, D-dimer, fibrinogen degradation products, creatinine, and urea was also higher in the patients who died. One of the 15 patients treated with ribavirin in the early stage could not survive (6.7%), whereas 11 of the 35 patients treated with ribavirin in the late stage could not survive (31.4%); this difference was statistically significant. However, there was no significant difference in mortality between the untreated group and the other two groups (i.e., patients who started antiviral treatment <5 days from the onset and those who started antiviral treatment ≥5 days from the onset). Moreover, there was no positive effect determined on clinical or laboratory parameters in SFTS patients treated with ribavirin. Also, it was observed that leukocyte levels and platelet levels took longer to return to normal. In Hefei, clinical features, prognostic factors, and risk factors associated with SFTS are similar to those in other areas. Patients who were given ribavirin did not have better survival rates than patients who were not given ribavirin.

Zhang Y ，Miao W ，Xu Y ，Huang Y ... -  《-》

The AST/ALT Ratio (De Ritis Ratio) Represents an Unfavorable Prognosis in Patients in Early-Stage SFTS: An Observational Cohort Study.

Severe fever with thrombocytopenia syndrome (SFTS), a widely prevalent infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV) that carries with it a high mortality rate, has emerged to be a public health concern. This study aimed to investigate the epidemiological and clinical characteristics of patients infected with SFTSV, seeking novel prognostic risk factors for SFTS. In this retrospective and cross-sectional study, confirmed SFTS patients from the First Affiliated Hospital of Anhui Medical University were enrolled from September 1, 2019, to December 12, 2020. Cases were analyzed for epidemiological, demographic, clinical, and laboratory data. Logistic regression models were used to assess the association between predictors and outcome variables. A generalized additive mixed model (GAMM) was conducted to analyze the trending shift of aspartate aminotransferase/alanine transaminase-ratio (AST/ALT-ratio) and platelet (PLT) in SFTS patients treated with ribavirin. p values ≤ 0.05 were considered statistically significant. Clinical and laboratory results of 107 hospitalized patients with SFTSV infection were retrospectively described. The mean age at onset of disease was 60.38 ± 11.29 years old and the ratio between male and female was 1:1.2. Fever and thrombocytopenia are hallmark features of SFTS. Furthermore, multiple cases also experienced neurological complications, gastrointestinal/skeletal muscle symptoms together with other non-specific clinical manifestations; laboratory dataset outcomes reported dysregulated levels for routine blood biomarkers, coagulation function, and biochemistry. Overall, 107 patients were segregated into two groups according to patient condition at the clinical endpoint (survivors/non-survivors). SFTS survivors had a higher level of PLT- counts, total protein (TP), and estimated glomerular filtration rate (eGFR), while levels of activated partial thromboplastin time (APTT), thrombin time (TT), D-dimer (D-D), fibrinogen degradation products (FDP), ALT, AST, AST/ALT-ratio, creatinine (Cr), creatine phosphokinase (CK) and procalcitonin (PCT) was higher in non-survivors. Results from univariate Cox regression revealed that elevated levels of FDP, TT, AST/ALT-ratio, PCT, as well as decreased eGFR level and presence of central nervous system symptoms (CNS), were significant predictors for SFTS prognostic, results from multivariate logistic regression analysis in three adjusted models showed AST/ALT-ratio and PCT were independent risk factors for the prognosis of SFTS patients. Kaplan-Meier survival analysis showed that SFTS patients with AST/ALT-ratio >2.683 were associated with a shorter futime (means survival time), therefore indicating an unfavorable prognosis. Treatment with ribavirin could increase PLT count while decreasing AST/ALT-ratio within SFTS patients. SFTS is an emerging infectious disease, possibly leading to multiple-organ injury; AST/ALT-ratio was an independent risk factor for the prognosis of SFTS patients. Further investigation should be performed in order to gain more knowledge on this disease and guide clinical management.

Wang L ，Xu Y ，Zhang S ，Bibi A ，Xu Y ，Li T ... -  《Frontiers in Cellular and Infection Microbiology》

Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients.

Severe fever with thrombocytopenia syndrome (SFTS) is a zoonotic infectious disease caused by the severe fever with thrombocytopenia syndrome virus (SFTSV). Endemic in East Asia, SFTS is characterized by an exceptionally high mortality rate. Presently, there is no established treatment for SFTS, particularly for patients in critical condition. In this study, we collected and analyzed laboratory and clinical data from 92 critically ill patients with SFTS treated at Weihai Municipal Hospital between 2019 and 2022. We hope that our study will provide some hints for the treatment of critically ill patients with SFTS. A total of 92 critically ill patients with SFTS were included in this study. Of these patients, 45 received treatment with therapeutic plasma exchange (TPE) and ribavirin (referred to as the TPE group), while the remaining patients received only ribavirin (referred to as the non-TPE group). Clinical and laboratory parameters were analyzed retrospectively. The results showed significant improvements in multiple laboratory parameters following treatment with TPE and ribavirin, including white blood cell and neutrophil count, lactate dehydrogenase, creatine kinase isoenzyme-MB, prothrombin time, activated partial thromboplastin time, D-Dimer, serum sodium and copies of virus genomes. The combination of TPE with ribavirin demonstrated a significant reduction in mortality rates, with a mortality rate of 20.0% in the TPE group compared to 40.4% in the non-TPE group (P = 0.033). Our findings suggest that critically ill patients with SFTS who received TPE and ribavirin experienced improvements in both clinical and laboratory parameters. These results indicate that TPE combined with ribavirin may represent a promising novel therapeutic approach for managing critically ill patients with SFTS. However, comparative studies of large sample size or randomized clinical trials are warranted to confirm the effectiveness of this combination therapy in the treatment of severe SFTS cases.

Song X ，Xu X ，Ren X ，Ruan X ，Bo J ... -  《-》

Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome.

Liu W ，Lu QB ，Cui N ，Li H ，Wang LY ，Liu K ，Yang ZD ，Wang BJ ，Wang HY ，Zhang YY ，Zhuang L ，Hu CY ，Yuan C ，Fan XJ ，Wang Z ，Zhang L ，Zhang XA ，Walker DH ，Cao WC ... -  《-》

Clinical laboratory parameters and fatality of Severe fever with thrombocytopenia syndrome patients: A systematic review and meta-analysis.

Wang Y ，Song Z ，Wei X ，Yuan H ，Xu X ，Liang H ，Wen H ... -  《PLoS Neglected Tropical Diseases》